Skip to main content

Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment

Osteoporosis International volume 22, pages 577–585 (2011)Cite this article

Abstract

Summary

In this pilot study, we demonstrated that women with osteopontin (OPN) over-expression show less resistance to postmenopausal osteoporosis than women with normal OPN levels. We hypothesized that the levels of plasma OPN could be used as a treatment indicator for intermittent parathyroid hormone (PTH)-treated menopausal osteoporosis. We demonstrated that plasma OPN levels could be used as a biomarker for early treatment response.

Introduction

Animal studies indicate that OPN-deficient mice are resistant to ovariectomy induced osteoporosis. Our pilot study also demonstrated women with OPN over expression may show less resistance to postmenopausal osteoporosis. The role of plasma OPN in PTH1-34-treated osteoporosis remains unclear.

Methods

From September 2005 to September 2006, 31 menopausal women over 45 years of age with severe osteoporosis were enrolled in our study. Subjects were treated with PTH1-34 subcutaneously at a dose of 20 μg/day. Plasma OPN levels and BMD of the lumbar spine and hip were measured using ELISA and dual-energy X-ray absorptiometry at baseline, 3, 6, and 9 months. Response to the treatment was assessed by the sequential change in bone mineral density and OPN expression using a general linear mixed model.

Results

The plasma OPN decreased sequentially and significantly throughout the 9-month treatment course from 20.75 ± 5.36 to 11.2 ± 4.37 ng/ml (p < 0.001). The sequential improvement in the T-score and Z-score was significant in the lumbar spine but not in the hip area. In the lumbar spine, when the plasma OPN decreased by 1 ng/ml the T-score increased by 0.0406 and the Z-score increased by 0.0572 of lumbar spine.

Conclusion

OPN levels are related to the anabolic effect of PTH in human postmenopausal osteoporosis. Plasma OPN levels could be used as a biomarker for early treatment response.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Ishijima M, Ezura Y, Kunikazu T, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M (2006) Osteopontin during tail-suspension-induced bone loss. Exp Cell Res 312:3075–3083

    CAS  Article  PubMed  Google Scholar 

  2. Rosen CJ, Bilezikian JP (2001) Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957–964

    CAS  Article  PubMed  Google Scholar 

  3. Seeman E, Delmas PD (2001) Reconstructing the skeletion with intermittent parathyroid hormone. Trends Endocrinol Metab 12:281–283

    CAS  Article  PubMed  Google Scholar 

  4. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79(4):262–272

    CAS  Article  PubMed  Google Scholar 

  5. Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J (2008) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84. Bone 44(1):113–119

    Article  PubMed  Google Scholar 

  6. Cosman F (2008) Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 15(6):495–501

    CAS  PubMed  Google Scholar 

  7. Nomura S, Takano-Yamamoto T (2000) Molecular events caused by mechanical stress in bone. Matrix Biol 19(2):91–96

    CAS  Article  PubMed  Google Scholar 

  8. Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144(5):2132–2140

    CAS  Article  PubMed  Google Scholar 

  9. Rittling SR, Matsumoto HN, Mckee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111

    CAS  Article  PubMed  Google Scholar 

  10. Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113

    CAS  Article  PubMed  Google Scholar 

  11. Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156–8160

    CAS  Article  PubMed  Google Scholar 

  12. Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A, Denhardt DT, Noda M (2001) Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142:1325–1332

    CAS  Article  PubMed  Google Scholar 

  13. Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M (2001) Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276:13065–13071

    CAS  Article  PubMed  Google Scholar 

  14. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M (2002) Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 99:4556–4561

    CAS  Article  PubMed  Google Scholar 

  15. Morinobu M, Ishijima M, Rittling SR, Tsuji K, Yamamoto H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin expression in osteoblasts and osteocytes during bone formation under mechanical stress in the calvarial suture in vivo. J Bone Miner Res 18:1706–1715

    CAS  Article  PubMed  Google Scholar 

  16. Chen Y, Bal BS, Gorski JP (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Boil Chem 267:24871–24878

    CAS  Google Scholar 

  17. Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265

    CAS  Article  PubMed  Google Scholar 

  18. MacNeli RL, Berry J, D’ErricoJ SC, Piotrowski B, Somerman MJ (1995) Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res 33:1–7

    Article  Google Scholar 

  19. Horton MA, Nesbit MA, Helfrich MH (1995) Interaction of osteopontin with osteoclast integrins. Ann N Y Acad Sci 760:190–200

    CAS  Article  PubMed  Google Scholar 

  20. Giachelli CM, Liaw L, Murry CE, Schwartz S, Almeida MM (1995) Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 760:109–126

    CAS  Article  PubMed  Google Scholar 

  21. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, DeBlois D, Giachelli CM (1997) Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 17:188–193

    CAS  PubMed  Google Scholar 

  22. Pichler R, Giachelli CM, Young B, Alpers CE, Couser WG, Johnson RJ (1995) The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Miner Electrolyte Metab 21:317–327

    CAS  PubMed  Google Scholar 

  23. Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1995) Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci 760:83–100

    CAS  Article  PubMed  Google Scholar 

  24. Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509–512

    CAS  Article  PubMed  Google Scholar 

  25. Kennedy OD, Brennan O, Rackard SM, Staines A, O'Brien FJ, Taylor D, Lee TC (2009) Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 27:303–309

    Article  PubMed  Google Scholar 

  26. Shapses SA, Cifuentes M, Spevak L, Chowdhury H, Brittingham J, Boskey AL, Denhardt DT (2003) Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 73(1):86–92

    CAS  Article  PubMed  Google Scholar 

  27. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M (2007) Osteopontin is required for mechanical stress-dependent signals to bone marrow cells. J Endocrinol 193(2):235–243

    CAS  Article  PubMed  Google Scholar 

  28. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB (2007) Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res A 83(1):136–144

    PubMed  Google Scholar 

  29. McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393

    Article  PubMed  Google Scholar 

  30. Malaval L, Wade-Guéye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amédée J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205(5):1145–1153

    CAS  Article  PubMed  Google Scholar 

  31. Yamane H, Sakai A, Mori T, Tanaka S, Moridera K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44(6):1055–1062

    CAS  Article  PubMed  Google Scholar 

  32. Ono N, Nakashima K, Rittling SR, Schipani E, Hayata T, Soma K, Denhardt DT, Kronenberg HM, Ezura Y, Noda M (2008) Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 283(28):19400–19409

    CAS  Article  PubMed  Google Scholar 

  33. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM (2002) Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 161(6):2035–2046

    CAS  PubMed  Google Scholar 

  34. Chang IC, Chiang TY, Yah KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporosis Int (in press)

  35. Wallace M, Shelkey M (2008) Katz index of independence in activities of daily living. Assisted Living Consult 14:21–22

    Google Scholar 

  36. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6:207

    Article  PubMed  Google Scholar 

  37. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, Maeda M, Uede T, Liaw L, Kinoshita N, Kawase I, Saeki Y (2004) Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316(3):809–815

    CAS  Article  PubMed  Google Scholar 

  38. Sugatani T, Alvarez U, Hruska KA (2003) PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 278(7):5001–5008

    CAS  Article  PubMed  Google Scholar 

  39. Walker CG, Ito Y, Dangaria S, Luan X, Diekwisch TG (2008) RANKL, osteopontin, and osteoclast homeostasis in a hyperocclusion mouse model. Eur J Oral Sci 116(4):312–318

    Article  PubMed  Google Scholar 

  40. Eastell R (2003) Pathogenesis of postmenopausal osteoporosis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. American Society for Bone and Mineral Research, Washington DC, pp 314–316

    Google Scholar 

  41. Recker R, Lappe J, Davies K, Heaney R (2000) Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 15:1965–1973

    CAS  Article  PubMed  Google Scholar 

  42. Abrahamsen B, Nissen N, Hermann AP, Hansen B, Bärenholdt O, Vestergaard P, Tofteng CL, Pors Nielsen S (2002) When should densitometry be repeated in healthy peri- and postmenopausal women?: the Danish osteoporosis prevention study. J Bone Miner Res 17:2061–2067

    CAS  Article  PubMed  Google Scholar 

  43. Li Y, Li A, Yang X, Weitzmann MN (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100(6):1370–1375

    CAS  Article  PubMed  Google Scholar 

  44. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM (2005) RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 38(2):161–170

    CAS  Article  PubMed  Google Scholar 

  45. Somayaji SN, Ritchie S, Sahraei M, Marriott I, Hudson MC (2008) Staphylococcus aureus induces expression of receptor activator of NF-kappaB ligand and prostaglandin E2 in infected murine osteoblasts. Infect Immun 76(11):5120–5126

    CAS  Article  PubMed  Google Scholar 

  46. Oh S, Kyung TW, Choi HS (2008) Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells. Mol Cells 26(5):486–489

    CAS  PubMed  Google Scholar 

  47. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J, Suthiphongchai T, Krishnamra N (2008) Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 42(3):535–546

    CAS  Article  PubMed  Google Scholar 

  48. Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti A, Bouxsein ML, Ferrari SL (2009) Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 24(5):775–784

    CAS  Article  PubMed  Google Scholar 

  49. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Investig 107:1055–1061

    CAS  Article  PubMed  Google Scholar 

  50. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184:118–130

    CAS  Article  PubMed  Google Scholar 

  51. Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030

    CAS  Article  PubMed  Google Scholar 

  52. Cheng SL, Lai CF, Blystone SD, Avioli LV (2001) Bone mineralization and osteoblast differentiation are negatively modulated by integrin alpha(v)beta3. J Bone Miner Res 16(2):277–288

    CAS  Article  PubMed  Google Scholar 

  53. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104(4):439–446

    CAS  Article  PubMed  Google Scholar 

  54. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM (1993) An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91(3):1138–1148

    CAS  Article  PubMed  Google Scholar 

  55. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R (2002) Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17(5):808–816

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from National Science Council (NSC98-2314-B-040-010-MY3) of Taiwan, Republic of China.

Conflicts of interest

None.

Author information

Affiliations

  1. Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo, N. Rd, Taichung, 40201, Taiwan

    T.-I. Chiang, I.-C. Chang, C.-H. Huang & Y.-W. Cheng

  2. Department of Orthopedic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan

    T.-I. Chiang & I.-C. Chang

  3. Department of Public Health, College of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan

    H.-S. Lee

  4. Institute of Public Health, College of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan

    H.-S. Lee

  5. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

    H. Lee

  6. Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Miaoli, Taiwan, Republic of China

    H. Lee

  7. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

    Y.-W. Cheng

Authors
  1. T.-I. Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I.-C. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C.-H. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y.-W. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y.-W. Cheng.

Additional information

T.-I. Chiang and I.-C. Chang equally contributed to this study.

The authors have no proprietary or financial interest in any material or device mentioned.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chiang, TI., Chang, IC., Lee, HS. et al. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int 22, 577–585 (2011). https://doi.org/10.1007/s00198-010-1327-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1327-x

Keywords

  • Bone mineral density
  • Osteopontin
  • Osteoporosis
  • Parathyroid hormone